[Remicade: six years of experience in immune-mediated inflammatory disorders].
Guillevin
L
L
Service de Médecine Interne, Centre de référence des maladies rares vascularites et sclérodermies, Hôpital Cochin, Paris.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D000069285:Infliximab; D010488:Polyarteritis Nodosa / Q000188:drug therapy / Q000276:immunology; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology; D012213:Rheumatic Fever / Q000188:drug therapy / Q000276:immunology; D025242:Spondylarthropathies / Q000188:drug therapy / Q000276:immunology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects / Q000276:immunology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab